Target Discovery - Isonostic™ Product Pipeline

Home

Main Menu

Home
About TDI
Isonostic™ Products
Corporate Communications
Careers
Contact Us
Site Map

PDF Viewer

Adobe Reader 6.0 or higher is required to view our PDF documents.

Isonostic™ Product Pipeline

Our initial product focus is oncology with assays that better guide therapeutic choices and lower the overall costs of cancer treatment. The glycosylation pathways in tumor cells are often defective, giving rise of cancer-specific isoforms of normal proteins in tumor cells. Known protein and nucleic acid biomarkers in cancer have proven to be poorly diagnostic and prognostic and research is showing that changes in the relative abundance of specific isoforms correlate better to the disease and its progression than changes in the amount of the parent protein, or gene transcript (mRNA), itself.

Learn more about Protein Isoforms

Isonostic™ Assays Currently Under Development

Tumor Aggressiveness in Prostate Cancer

Therapy Selection for In Situ Ductal Carcinoma (Breast Cancer)

Chemotherapy Selection for Ovarian Cancer

Isonostic™ Product Partnerships

Isonostic™ Assays are potentially useful for diagnostic applications beyond cancer. TDI partners with pharmaceutical companies to develop Isonostic™ assays to profile patients for drug efficacy and toxicology (theranostics). TDI will consider collaborations with others outside of our corporate focus in cancer..

Learn more about Theranostics

Learn more about Collaborating with TDI

The Future of Isonostics™

TDI will establish and extend its proprietary position in the market by owning the clinical diagnostic rights to isoforms of known biomarkers. Isoforms are currently very difficult to identify and few are established in the literature. TDI will in-license intellectual property to known isoform biomarkers where available to speed Isonositc™ product development, but our mass defect technology uniquely positions us to both discover and validate isoforms in known biomarkers. Once the clinical relevance of specific isoforms as biomarkers are validated, we can then exploit them in our clinical Isonostic™ platform or in a traditional immunodiagnostic format.

Learn more about the Technology

Isonostic™ assays have the potential to be displacing technologies in several segments of the broader immunodiagnotic and molecular diagnostic segments, which includes genomic and proteomic-based testing (an existing $7-12B market).